Although social anxiety disorder (SAD) is one of the most prevalent psychiatric disorders in epidemiological surveys, concepts of social anxiety have varied from time to time and place to place. In recent years, however, similar assessments and treatments have been utilized across the world.
Methods
In this paper, current concepts of SAD in the West and the partially related condition known as taijin kyofusho (TKS) in the East are summarized, and trials of selective serotonin reuptake inhibitors (SSRIs) that have been undertaken in both the United States/Europe and in Japan for social anxiety symptoms are reviewed.
Results
Despite differences in the conceptualization of SAD and TKS, social anxiety is a prevalent symptom in many parts of the world. Fluvoxamine is more effective than placebo in randomized controlled trials of SAD in the West and the East.
Conclusions
Patients suffering from SAD in different parts of the world share many features in common, and certain SSRIs are an effective treatment for this condition globally.
MageeWJEatonWWWittchenHU. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:159–168.
2.
FehmLPelissoloAFurmarkT. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005;15:453–462.
3.
BallengerJCDavidsonJALecrubierY. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59:54–60.
4.
WakefieldJCHorwitzAVSchmitzMF. Are we over-pathologizing the socially anxious? Social phobia from a harmful dysfunction perspective. Can J Psychiatry. 2005;50:317–319.
5.
MullerJEKoenLSteinDJ. The spectrum of social anxiety disorders. In: BandelowB, SteinDJ, eds. Social anxiety disorder.New York, NY: Marcel Dekker; 2004.
6.
MatsunagaHKiriikeNMatsuiT. Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?Int J Neuropyschopharmacol. 2001;4:231–237.
7.
KirmayerLJ. The place of culture in psychiatric nosology: taijin kyofusho and DSM-III-R. J Nerv Ment Dis. 1991;179:19–28.
8.
OnoYYoungJ.Taijin Kyofusho in Japan: Social phobia or culture-bound syndrome?Psychiatric Networks. 2000;3:47–58.
9.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed.Washington, DC: American Psychiatric Association; 1994.
10.
MerikangasKRAvenevoliSAcharyyaS. The spectrum of social phobia in the Zurich Cohort Study of Young Adults. Biol Psychiatry. 2002;51:81–91.
11.
ChaviraDASteinMB. The shyness spectrum. CNS Spectr. 1999;4:20–26.
12.
KleinknechtRADinnelDLKleinknechtEE. Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin Kyofusho. J Anxiety Disord. 1997;11:157–177.
13.
MaedaFNathanJH. Understanding taijin kyofusho through its treatment, Morita therapy. J Psychosom Res. 1999;46:525–530.
14.
KinoshitaYChenJRapeeRM. Cross-cultural study of conviction subtype Taijin kyofu: proposal and reliability of Nagoya-Osaka diagnostic criteria for social anxiety disorder. J Nerv Ment Dis. 2008;196:307–313.
15.
ChangSC. Social anxiety (phobia) and east Asian culture. Depress Anxiety. 1997;5:115–120.
16.
TakahashiT.Social phobia syndrome in Japan. Compr Psychiatry. 1989;30:45–52.
17.
OnoYYoshimuraKYamauchiK. Taijin Kyofusho in a Japanese community population. Transcult Psychiatry.2001;38:506–514.
18.
LiebowitzMR. Social phobia. In: BanTA, PichotP, PoldingerW, eds. Modern problems of pharmacopsychiatry. Basel, Switzerland; 1987.
19.
SteinMBSteinDJ. Social anxiety disorder. Lancet. 2008;371:1115–1125.
20.
SchwartzCEWrightCIShinLM. Inhibited and uninhibited infants “grown up”: adult amygdalar response to novelty. Science. 2003;5627:1952–1953.
21.
SmollerJWRosenbaumJFBiedermanJ. Association of a genetic marker at the corticotropinreleasing hormone locus with behavioral inhibition. Biol Psychiatry. 2003;54:1376–1381.
22.
SteinDJ. Cognitive-affective neuroscience of depression and anxiety disorders. London, UK: Martin Dunitz; 2003.
23.
SteinDJWestenbergHGLiebowitzMR. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry. 2002, 63(suppl 6):12–19.
24.
NesseRMWilliamsGC. Why we get sick: The new science of Darwinian medicine. New York, NY: Vintage Books; 1994.
25.
DarwinC.The Expression of Emotion in Man and Animals. London, UK: John Murray; 1872.
26.
SteinDJBouwerC.A neuro-evolutionary approach to the anxiety disorders. J Anxiety Disord. 1997;11:409–429.
27.
SteinDJ. Advances in understanding the anxiety disorders: the cognitive-neuroscience of “false alarms.”Ann Clin Psychiatry. 2006;18:173–182.
28.
LiebowitzMRFyerAJGormanJM. Phenelzine in social phobia. J Clin Psychopharmacol. 1986;6:93–98.
29.
DavidsonJRTuplerLAPottsNL. Treatment of social phobia with benzodiazepines. J Clin Psychiatry. 1994, 55(suppl):28–32.
30.
van VlietIM, den BoerJA, WestenbergH.Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacol. 1994;115:128–134.
31.
SteinMBFyerAJDavidsonJR. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156:756–760.
32.
SteinMBLiebowitzMRLydiardRB. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708–713.
33.
BaldwinDBobesJSteinDJ. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999;175:120–126.
34.
AllgulanderC.Paroxetine in social anxiety disorder: a randomised placebo-controlled study. Acta Psychiatr Scand. 1999;100:193–198.
35.
van AmeringenMA, LaneRM, WalkerJR, . Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:275–281.
36.
KatzelnickDJKobakKAGreistJH. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368–1371.
37.
KasperSSteinDJLoftH. Escitalopram is effective and well tolerated in the treatment of social anxiety disorder: a randomised, placebo-controlled, flexible-dose study. Br J Psychiatry. 2005;186:222–226.
38.
LaderMStenderKBurgerV. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: a randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19:241–248.
39.
ManganoRM. Treating social anxiety disorder with venlafaxine extended release. Eur Neuropsychopharmacol. 2002;12:358.
40.
van der LindenGJ, SteinDJ, van BalkomAJ.The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a metaanalysis of randomized controlled trials. Int Clin Psychopharmacol.2000, 15(suppl 2):15–24.
41.
BlancoCSchneierFRSchmidtAB. Pharmacological treatment of social anxiety disorder: a metaanalysis. Depress Anxiety. 2003;18:29–40.
42.
SteinDJIpserJCBalkomAJ. Pharmacotherapy for social anxiety disorder. Cochrane Database Syst Rev. 2004;CD001206.
43.
SteinDJVersianiMHairT. Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Arch Gen Psychiatry. 2002;59:1111–1118.
44.
WalkerJRvan AmeringenMA, SwinsonR, . Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000;20:636–644.
45.
RandallCLJohnsonMRThevosAK. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14:255–262.
46.
MarchJSEntusahARRynnM. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62:1149–1154.
47.
BlomhoffSHaugTTHellströmK. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179:23–30.
48.
HofmannSGMeuretAESmitsJA. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298–304.
49.
BandelowBZoharJHollanderE, and the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry.2002;3:171–199.
50.
ShindoMShioiriTKuwabaraH. Clinical features and treatment outcome in Japanese patients with social anxiety disorder: chart review study. Psychiatry Clin Neurosci. 2006;60:410–416.
51.
KobayashiNKurauchiSSawamuraT. The effect of paroxetine on Taijinkyofusho: a report of three cases. Psychiatry. 2003;66:262–267.
52.
NagataTvan VlietI, YamadaH, . An open trial of paroxetine for the “offensive subtype” of taijin kyofusho and social anxiety disorder. Depress Anxiety. 2006;23:168–174.
53.
NagataTOshimaJWadaA. Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder. International Journal of Psychiatry in Clinical Practice. 2003;7:107–112.
54.
AsakuraSTajimaOKoyamaT.Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007;10:263–274.
55.
KuzmaJMBlackDW. Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders. Curr Psychiatry Rep. 2004;6:268–273.
56.
KitanishiKMoriA.Morita therapy: 1919 to 1995. Psychiatry Clin Neurosci. 1995;49:245–254.
57.
SteinDJMatsunagaH.Cross-cultural aspects of social anxiety disorder. Psychiatr Clin North Am. 2001;24:773–782.
58.
SteinDJWilliamsD.Cross-cultural aspects of anxiety disorders. In: SteinDJ, HollanderE.The American Psychiatric Publishing textbook of anxiety disorders. Washington, DC: American Psychiatric Publishing, Inc.; 2002.
59.
SteinDJ. Cross-cultural psychiatry and the DSM-IV. Compr Psychiatry. 1993;34:322–329.
60.
PrinceRTcheng-LarocheF.Culture-bound syndromes and international disease classifications. Cult Med Psychiatry. 1987;11:3–20.
NakamuraKKitanishiKMiyakeY. The neurotic versus delusional subtype of taijin-kyofusho: their DSM diagnoses. Psychiatry Clin Neurosci. 2002;56:595–601.
66.
SuzukiKTakeiNIwataY. Do olfactory reference syndrome and Jiko-shu-kyofu (a subtype of Taijin-kyofu) share a common entity? Acta Psychiatr Scand. 2004;109:150–155.
67.
RectorNAKocovskiNLRyderAG. Social anxiety and the fear of causing discomfort to others. Cognitive Therapy and Research. 2006;30:279–296.
68.
KimJRapeeRMGastonJF. Symptoms of offensive type Taijin-Kyofusho among Australian social phobics. Depress Anxiety. 2008;25:601–608.
69.
ClarvitSRSchneierFRLiebowitzMR. The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. J Clin Psychiatry. 1996;57:523–527.
70.
ChoyYSchneierFRHeimbergRG. Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder. Depress Anxiety. 2008;25:230–240.
71.
OnoYYoshimuraKSueokoR. Avoidant personality disorder and taijin kyoufu: sociocultural implications of the WHO/ADAMHA International Study of Personality Disorders in Japan. Acta Psychiatr Scand.1996;93:172–176.
72.
EmeryNJ. The eyes have it: the neuroethology, function and evolution of social gaze. Neurosci Biobehav Rev. 2000;24:581–604.
73.
SteinDJLeRoux L, BouwerC, . Is olfactory reference syndrome on the obsessive-compulsive spectrum?: Two cases and a discussion. J Neuropsychiatry Clin Neurosci. 1998;10:96–99.
74.
PhillipsKA. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin. 1998, 62(4 suppl A):33–48.
